[1]常娅妮,刘建中,晋建华.131I治疗先天性甲状腺单叶缺如合并Graves病甲巯咪唑治疗后复发一例[J].国际放射医学核医学杂志,2018,(2):189-191.[doi:10.3760/cma.j.issn.1673-4114.2018.02.017]
　Chang Yani,Liu Jianzhong,Jin Jianhua.Case of 131I therapy in a patient with congenital absence of single thyroid gland lobe combined with Graves’ disease and recurrence after methimazole therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):189-191.[doi:10.3760/cma.j.issn.1673-4114.2018.02.017]
点击复制

131I治疗先天性甲状腺单叶缺如合并Graves病甲巯咪唑治疗后复发一例(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第2期
页码:
189-191
栏目:
病例报告
出版日期:
2018-05-09

文章信息/Info

Title:
Case of 131I therapy in a patient with congenital absence of single thyroid gland lobe combined with Graves’ disease and recurrence after methimazole therapy
作者:
常娅妮;  刘建中;  晋建华
030001 太原, 山西医科大学第一医院核医学科
Author(s):
Chang Yani;  Liu Jianzhong;  Jin Jianhua
Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan 030001, China
DOI:
10.3760/cma.j.issn.1673-4114.2018.02.017
摘要:
笔者报道了1例131I治疗先天性甲状腺单叶缺如合并Graves病甲巯咪唑治疗后复发的病例，从临床症状、血清学化验、甲状腺超声及颈胸部SPECT/CT融合显像等方面分析该病例特点，并通过文献复习加深了对先天性甲状腺单叶缺如合并Graves病的认识。甲状腺单叶缺如合并Graves病患者在规律口服抗甲状腺药物治疗后出现复发，应尽早选择131I治疗。131I治疗仍是先天性甲状腺单叶缺如伴Graves病甲巯咪唑治疗后复发患者较为理想的方法。
Abstract:
We report a case of 131I therapy in a patient with congenital absence of single thyroid gland lobe combined with Graves’ disease and recurrence after methimazole therapy. We analyzed the characteristics of this case on the basis of clinical symptoms; auxiliary examination, including serological tests, thyroid ultrasound, and SPECT/CT fusion imaging of neck and chest. Understanding about the congenital absence of single thyroid gland lobe combined with Graves’ disease was deepened through literature review. 131I therapy must be employed as early as possible when a patient with congenital absence of single thyroid gland lobe combined with Graves’ disease exhibits recurrence after regular oral antithyroid drug therapy. 131I therapy is still an ideal method for patients with congenital absence of single thyroid gland lobe combined with Graves’ disease and recurrence after methimazole therapy.

参考文献/References:

[1] Campennì A, Giovinazzo S, Curtò L, et al. Thyroid hemiagenesis, Graves’ disease and differentiated thyroid cancer:a very rare association:case report and review of literature[J]. Hormones (Athens), 2015,14(3):451-458. DOI:10.14310/horm.2002.1606.
[2] Tonacchera M, Banco ME, Montanelli L, et al. Genetic analysis of the PAX8 gene in children with congenital hypothyroidism and dysgenetic or eutopic thyroid glands:identification of a novel sequence variant[J]. Clin Endocrinol (Oxf), 2007, 67(1):34-40. DOI:10.1111/j.1365-2265.2007.02831.x.
[3] De Sanctis V, Soliman AT, Di MS, et al. Thyroid hemiagenesis from childhood to adulthood:review of literature and personal experience[J]. Pediatr Endocrinol Rev, 2016, 13(3):612-619. DOI:10.4084/mjhid.20017.001.
[4] 中华医学会核医学分会. 131I治疗格雷夫斯甲亢指南(2013版)[J].中华核医学与分子影像杂志, 2013, 33(2):83-95. DOI:10.3760/cma.j.issn.2095-2848.2013.02.002. Chinese society of nuclear medicine. Guidelines of 131I therapy in Graves hyperthyroidism(2013 Edition)[J]. Chin J Nucl Med Mol Imaging, 2013, 33(2):83-95.
[5] 梁雯丽, 郑艳, 李娜,等. Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J]. 国际放射医学核医学杂志, 2016, 40(1):13-16. DOI:10.3760/cma.j.issn.1673-4114.2016.01.003. Liang WL, Zheng Y, Li N, et al. Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J]. Int J Radiat Med Nucl Med, 2016, 40(1):13-16.
[6] Campennì A, Giovinazzo S, Curtò L, et al. Thyroid hemiagenesis, Graves’ disease and differentiated thyroid cancer:a very rare association:case report and review of literature[J]. Hormones (Athens), 2015,14(3):451-458. DOI:10.14310/horm. 2002.1606.
[7] Melnick JC, Stemkowski PE. Thyroid hemiagenesis (hockey stick sign):a review of the world literature and a report of four cases[J]. J Clin Endocrinol Metab, 1981, 52(2):247-251. DOI:10.1210/jcem-52-2-247.
[8] Bergami G, Barbuti D, Di MM. Echographic diagnosis of thyroid hemiagenesis[J]. Minerva Endocrinol, 1995, 20(3):195-198.
[9] Ruchala M, Szczepanek E, Sowiński J. Diagnostic value of radionuclide scanning and ultrasonography in thyroid developmental anomaly imaging[J]. Nucl Med Rev Cent East Eur, 2011, 14(1):21-28. DOI:10.5603/NMR.2011.0005.
[10] De Remigis P, D’Angelo M, Bonaduce S, et al. Comparison of ultrasonic scanning and scintiscanning in the evaluation of thyroid hemiagenesis[J]. J Clin Ultrasound, 1985, 13(8):561-563. DOI:10.1002/1097-0096(199010)13:8<561::AID-JCU1870130808>3.0.CO;2-X.

备注/Memo

备注/Memo:
收稿日期:2017-12-09。
通讯作者:晋建华,Email:jjh1225@126.com
更新日期/Last Update: 2018-05-09